Ali Hamad, Alahmad Barrak, Al-Mulla Fahd
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Department of Translational Medicine, Dasman Diabetes Institute (DDI), Dasman, Kuwait.
BMC Nephrol. 2025 Jun 4;26(1):279. doi: 10.1186/s12882-025-04217-w.
GLP-1 receptor agonists revolutionized diabetes therapy and offer cardiorenal protection in diabetic kidney disease. Their potential in Autosomal Dominant Polycystic Kidney Disease (ADPKD) is now being explored. Preclinical findings and metabolic improvements (obesity, hypertension, inflammation) indicate promise. Further clinical studies are required to ensure efficacy and safety before clinical integration can be considered. Clinical trial number: Not applicable.
胰高血糖素样肽-1（GLP-1）受体激动剂彻底改变了糖尿病治疗方式，并为糖尿病肾病提供心脏肾脏保护作用。目前正在探索其在常染色体显性多囊肾病（ADPKD）中的潜力。临床前研究结果及代谢改善情况（肥胖、高血压、炎症）显示出应用前景。在考虑临床应用之前，还需要进一步的临床研究以确保其疗效和安全性。临床试验编号：不适用。
